| Philadelphia chromosome positive chronic myelogenous leukemia
Scemblix vs Sprycel
Side-by-side clinical, coverage, and cost comparison for philadelphia chromosome positive chronic myelogenous leukemia.Deep comparison between: Scemblix vs Sprycel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSprycel has a higher rate of injection site reactions vs Scemblix based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sprycel but not Scemblix, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Scemblix
Sprycel
At A Glance
Oral
Once or twice daily
BCR-ABL1 tyrosine kinase inhibitor
Oral
Once daily
BCR-ABL/SRC kinase inhibitor
Indications
- Philadelphia chromosome positive chronic myelogenous leukemia
- Philadelphia chromosome positive chronic myelogenous leukemia
- B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
Dosing
Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase 80 mg orally once daily or 40 mg orally twice daily, taken without food; avoid food for at least 2 hours before and 1 hour after each dose.
Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase with T315I mutation 200 mg orally twice daily at approximately 12-hour intervals, taken without food; avoid food for at least 2 hours before and 1 hour after each dose.
Philadelphia chromosome positive chronic myelogenous leukemia (adults) Chronic phase: 100 mg orally once daily; accelerated or blast phase: 140 mg orally once daily. Tablets must be swallowed whole, with or without food.
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 (adults) 140 mg orally once daily, swallowed whole with or without food.
Philadelphia chromosome positive chronic myelogenous leukemia, B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 (pediatric patients >=1 year) Weight-based once daily: 40 mg (10 to <20 kg), 60 mg (20 to <30 kg), 70 mg (30 to <45 kg), 100 mg (>=45 kg); Ph+ ALL pediatric patients receive SPRYCEL in combination with chemotherapy for up to 2 years.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, arthralgia, diarrhea
Serious Myelosuppression, pancreatic toxicity, hypertension, hypersensitivity, cardiovascular toxicity
Most common (>=10%) Fluid retention, pleural effusion, superficial localized edema, diarrhea, headache, musculoskeletal pain, rash, fatigue, nausea, dyspnea, hemorrhage, abdominal pain
Serious Myelosuppression, bleeding-related events, fluid retention, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, hepatotoxicity
Postmarketing Hepatitis B virus reactivation, atrial fibrillation/atrial flutter, interstitial lung disease, chylothorax, Stevens-Johnson syndrome, nephrotic syndrome, thrombotic microangiopathy, hepatotoxicity
Pharmacology
Asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor that inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein by binding to the ABL myristoyl pocket, with activity against wild-type BCR::ABL1 and several mutant forms including the T315I mutation.
Dasatinib is a multi-targeted kinase inhibitor that at nanomolar concentrations inhibits BCR-ABL, SRC-family kinases (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRbeta, and can overcome imatinib resistance arising from BCR-ABL kinase domain mutations, activation of SRC-family signaling pathways, or multi-drug resistance gene overexpression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Scemblix
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Sprycel
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Scemblix
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Sprycel
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Scemblix
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Sprycel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Chronic Myeloid Leukemia (C.M.L.) - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Chronic Myeloid Leukemia (C.M.L.) - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ScemblixView full Scemblix profile
SprycelView full Sprycel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.